1 clinical trials submitted successfully – session #12 heritage gallery presenters: laura williams...
Post on 21-Dec-2015
218 views
TRANSCRIPT
1
Clinical Trials Submitted Successfully – Session #12Clinical Trials Submitted Successfully – Session #12
Heritage GalleryHeritage Gallery
Presenters: Presenters:
Laura Williams – Sponsored Projects AdministrationLaura Williams – Sponsored Projects Administration
Debra Dykhuis – Office of Clinical ResearchDebra Dykhuis – Office of Clinical Research
Bridget Foss – Sponsored Projects AdministrationBridget Foss – Sponsored Projects Administration
2
According to clinicaltrials.gov, there are approximately how many open clinical studies underway
in the state of Minnesota?
Clinical Trials Trivia Time
1,231
3
Order of Presentation
Laura Williams – Feasibility Considerations Laura Williams – Feasibility Considerations in Clinical Trialsin Clinical Trials
Debra Dykhuis – Budgetary Considerations Debra Dykhuis – Budgetary Considerations in Clinical Trialsin Clinical Trials
Bridget Foss - SPA Submission Processes and ShortcutsBridget Foss - SPA Submission Processes and Shortcuts
4
Feasibility Considerations in Clinical TrialsFeasibility Considerations in Clinical Trials
5
What We’ll Cover Today Protocol Review
Considerations Ethical Considerations Business Considerations Scientific Review Institutional Review Regents Policies
Certainly not to be ignored, but not covered today:FDAGCPICHInvestigator-sponsored clinical trials
6
Protocol Review Considerations
7
◦ Population
◦ Staff
◦ Space
◦ Technical capability
Feasibility
8
Profitability
◦ Cost per subject
◦ Complexity of protocol
◦ Duration of study
◦ Survivability
9
Scientific Merit
◦ Adequate study design
◦ Main hypothesis
◦ Blinding, randomization
◦ Biostatistical methodology
◦ Endpoints
◦ Publishability
10
Ethical Considerations
Target population Safety Severity of disease Availability of alternative treatments Side effects Peds / Elderly Underserved populations
11
Business Considerations
Frequency and complexity of monitoring visits Closeout visits Funder resources and assistance during the trial Working with the PI Cost sharing Multi-departmental
12
Business Considerations
CRO involvement Past dealings with sponsor History of timely payments (or not!) SIV Process
13
Business Considerations – The Clinical Trial Agreement
Publications◦ University’s policies and continuing tax status are
dependent on fulfilling our threefold mission: Research and Discovery Teaching and Learning Outreach and Public Service
Intellectual Property◦ Terms must also be respondent to the University
research mission◦ Principles of exercising academic freedom
Indemnification and Subject Injury Payments
◦ Important to understand these are negotiable◦ SPA will defer to the coordinator/PI
14
Scientific Review
To be performed by independent, peer reviewers – no one from the research team
One of three methods must be utilized
1. Full peer review by grant committee of NIH, NSF or a foundation – excludes industry sponsored clinical trials; or
2. U of M scientific review committees;
or
3. CPRC provides initial evaluation and review of all University of Minnesota clinical cancer research protocols, and monitors and renews the protocols annually. Those with low success may be terminated.
15
Scientific Review
General Clinical Research Center (GCRC) Scientific Advisory
Committee – only if GCRC center is utilized
Protocol Review and Data Use (PRDU) - protocols involving solid
organ transplant
Interdisciplinary Site Specific Committee – translational
Others – Surgery, OB/Gyn
Any appropriately constituted departmental or collegiate – at least two reviewers reach consensus on science, documentation of the review process filed with the college-level associate dean
Required prior to IRB submission
16
Regents Policies Openness in Research - Subd. 1
◦ The University shall not accept support from any source for research under a contract or grant that prohibits the disclosure of the research relationship, the nature of the research…..
IP Sharing◦ Commercialization activities are encouraged per Policy◦ Can not inhibit open research◦ Research should result in generation and
dissemination of new knowledge Ethics
◦ Just the appearance of impropriety is to be avoided
17
Institutional Research Review and Committees
IRB – Human subjects COI – Financial or other types of potential
conflicts of interest HIPAA ICD IBC - recombinant DNA, infectious agents or
biologically derived toxins AURPAC - ionizing radiation
18
Reference Resource http://cflegacy.research.umn.edu/irb/about/ http://cflegacy.research.umn.edu/subjects/ http://cflegacy.research.umn.edu/irb/
ScientificReview/index.cfm www.umn.edu/regents/polindex.html http://www.ospa.umn.edu/index.html
Questions:Laura Williams, Principal Grant and Contract Administrator
19
Estimating Personnel Time and Optimizing Payment TernsDebra Dykhuis
02.17.2009
Clinical Trials Submitted Successfully
20
The crystal ball approach to estimating personnel time……
“…there are many ways of losing money. Women are the most fun. Gambling is the fastest. Research is the most certain.”
Lord Hives,Former Chairman of Rolls Royce
21
What is at stake?
Quality of the data Speed of accrual Attention to compliance Prospects of getting future research funding Staff burnout/turnover Jobs
22
What can be done?
Have a clear clinical trial plan Abandon the notion that guessing is the best
we can do Abandon the notion that the sponsor, agency,
or center knows what it will cost to do the trial (and has our best interests at heart)
Create a column for every time point data will be collected
Create a row for every person who will have a job to do
23
What can be done?
Consider what each person will be required to do for each visit and write it down
Attach an estimate of time to do each part of the work
Ask the person who will be doing it what they think of the estimate
Adjust as needed and enter the number of hours required for each protocol time point or visit
24
What can be done?
Be sure to consider time staff will spend at research meetings, on subject recruitment, the time to prepare for research subject visits and the follow-up that might be needed, event reporting, managing interactions with monitors, and data queries
For industry trials, include time for start-up and close out, regulatory documents, amendment processing, etc.
25
What do we know? Reviewed time data for 20 clinical trials
completed 2005-2007 Areas of cancer, solid organ transplant,
critical care, rare diseases Average time per study visit for a research
coordinator – 11 hours Average start-up time – 45 hours for
regulatory processes; 24 hours for clinical research coordinator
26
Applying what we know
Approximately 35% of an employee’s appointment time is consumed by vacation/sick leave, breaks, and other work that may not be directly related to a clinical trial
Consider this when writing budgets that require budgeting by FTEs
Example: a .5 research coordinator on a solid organ transplant study will be able to manage about 61 visits per year (at 11 hrs/visit)
27
Optimizing contract payment terms in agreements with industry Start date: terms should allow payment for work as
soon as it starts End date: should be “until all study work completed” Start-up and close-out costs: should be non-
refundable, unrelated to subject enrollment, payable on contract execution
Final payment: not more than 10% withheld Payment frequency: no less than quarterly for work
performed Items payable on invoice: limit these to items that
will truly be sporadic or unpredictable (not as a way of making reimbursement conditional)
28
Resources
Good Clinical Practice Protocol Template
Clinical Trial Budget Template
29
SPA ProcessesBridget Foss02.17.2009
Clinical Trials Submitted Successfully
30
This process allows SPA to negotiate theAgreement while the department is
completing budget negotiations.
Expedited PRF Package Includes: Draft PRF signed by Principal Investigator Draft Budget Draft Protocol Agreement (if available)
* It is essential that a sponsor contact is included on the PRF for this process to be effective.
Expedited Process for Industry Funded Clinical
Trials
31
Proposals, non-industry funded trials, andindustry funded trials after budgetnegotiation require the following:
Fully Routed PRF Final Protocol Negotiated Budget TASCS Billing Grid
Standard (“Final”) PRF Package
32
Is the trial investigator sponsored?
Is the project an animal clinical trial or pre-clinical research?
What is the appropriate F&A rate for this particular project?Industry Funded Clinical Trial: 26% TDCNon-Industry Funded Clinical Trial: 51% MTDC
Pre-Clinical Research: 51% MTDC
Questions to Consider Questions to Consider During PRF PrepDuring PRF Prep
33
Compliance Checks
Compliance requirements for Investigators: Approved REPA Completed RCR training (or approved
extension)
SPA also checks the RSPP database for human subjects, animal subjects and/or IBC approvals. Please note that the title used on the PRF needs to match the protocol title approved by RSPP.
34
If costs are incurred prior to execution of the agreement, an advance account should be requested.
SPA attempts to insert language allowing pre-award costs; however, all pre-award costs are incurred at the department’s risk.
Departments often request advance account in order to complete Fairview submissions.
Advance Account
35
SPA reviews and negotiates the contract language for conformity with University policy, and works in consultation with the Office of General Counsel, the Office of Technology Commercialization, and the Principal Investigator.
Problem clauses may include publication, confidentiality, intellectual property, and indemnification.
Negotiations take time!
Agreement Negotiation
36
If expedited process is used, SPA will not execute the agreement until it receives the final PRF package.
Compliance issues need to be resolved prior to execution and award set up.
Agreements are sent to the investigators for final review and or approval prior to University execution.
Agreement Execution
37
Award Set Up for Industry Funded Clinical Trials
Fixed price industry funded clinical trials are set up in accordance with the University procedure “Handling Industry Sponsored Clinical Trial Research Agreements.”
Accounts are initially set up for $0. Dollars are set up on the Project by Sponsored Financial Reporting as funds are received. It is the department’s responsibility to re-budget dollars into the appropriate accounts based on the budget.
38
Award Set Up for Non-Industry Funded Clinical
Trials Cost reimbursable awards and non-industry
funded trials are set up based on the department provided and sponsor approved budget for the current period.
Account set up, regardless of funding source, is subject to the terms and conditions of the agreement governing the project. Each project is handled on a case by case basis.
39
B&I Expedited Procedure: http://www.ospa.umn.edu/policiesandprocedures/B&Iclinicaltrials.html
F&A Rates: http://www.ospa.umn.edu/forms/rates/F&A.html
Advance Account Policy: http://www.fpd.finop.umn.edu/groups/ppd/documents/policy/Preaward_Policy.cfm
Openness in Research policy: http://www1.umn.edu/regents/policies/academic/Openness_in_Research.pdf
Handling Industry-Sponsored Clinical Trial Research Agreements: http://www.fpd.finop.umn.edu/groups/ppd/documents/procedure/clinical_trials_proc1.cfm
References
40